Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09BDD
|
|||
| Drug Name |
1,2,4-triazole [4,3-a]quinoxaline derivative 1
|
|||
| Synonyms |
PMID27321640-Compound-33
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BOEHRINGER INGELHEIM INTERNATIONAL GmbH
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H11ClN4
|
|||
| Canonical SMILES |
CC1=NC2=CC=CC=C2N3C1=NN=C3C4=CC=CC=C4Cl
|
|||
| InChI |
1S/C16H11ClN4/c1-10-15-19-20-16(11-6-2-3-7-12(11)17)21(15)14-9-5-4-8-13(14)18-10/h2-9H,1H3
|
|||
| InChIKey |
CTBSIWZADWNGPL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 10A (PDE10) | Target Info | Inhibitor | [1] |
| Phosphodiesterase 2A (PDE2A) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Phosphodiesterase 10A (PDE10) | Target's Patent Info | [1] | |
| Phosphodiesterase 2A (PDE2A) | Target's Patent Info | [1] | ||
| KEGG Pathway | Purine metabolism | |||
| Morphine addiction | ||||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.